Dr. Alan Sandler, Dr. James Cassidy Join Medelis' Medical Advisory Board
We’re pleased to announce more company news today: Two leading oncology researchers, Dr. Alan Sandler of Portland, Oregon and Dr. James Cassidy of Glasgow, Scotland, have joined our Medical Advisory Board.
Alan Sandler, M.D. is a Professor of Medicine in the Division of Hematology & Medical Oncology, Department of Medicine, at Oregon Health & Science University in Portland, Oregon. Board-certified in Medical Oncology and Internal Medicine, he serves as the Division Chief of the Hematology & Medical Oncology Division and holds the DeArmond Chair for Clinical Cancer Research. He specializes in cancer and blood disorders with a special interest in lung cancer, and he is widely considered a key opinion leader in the development of targeted therapies in the treatment of thoracic malignancies.
Dr. Sandler is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group, where he serves as the Co-Chair of the Thoracic Committee.
James Cassidy, MBChB, MD, MSc, FRCP is a leading researcher in anti-sickness compounds and innovative approaches to drug-resistant tumors. Dr. Cassidy is a Professor of Oncology and heads the Medical Oncology Department and the Division of Cancer Sciences & Molecular Pathology at the University of Glasgow, Scotland. He heads the Centre for Oncology and Applied Pharmacology (COAP) and has his own Cancer Research UK (CRUK) lab based program exploring methods for gene and drug delivery. He also heads the Glasgow Experimental Cancer Medicine Centre (ECMC) which is focused on Good Laboratory Practice (GLP) quality assured assessments of molecular markers, pharmacodynamics and pharmacokinetics of novel agents at the clinical/lab translational interface.
On the clinical side, Dr. Cassidy runs a service for colorectal cancer patients and has a major commitment to early phase clinical studies of innovative therapies.
In our formal news release, Medelis president and CEO Bob Bosserman says, “Medelis is very privileged to add Dr. Cassidy and Dr. Sandler to our distinguished group of expert advisors. They strengthen our ability to provide clients with cutting-edge expertise and assistance in the development and advancement of personalized therapies, which will ultimately help improve the treatment options for clinicians. They also further strengthen our relationship with the clinical research community that directly cares for cancer patients and closely understands their needs.”
“Both of these physician/researchers can now bring their clinical experience to bear on the unique study design and management issues that our biotechnology and pharmaceutical clients face in the oncology drug development process,” Bosserman adds.
You can find Dr. Sandler’s full bio here and Dr. Cassidy’s bio here.
